Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
Chun‐Yu Chen, Brian Hutzen, Mary Frances Wedekind, et al.
Oncolytic Virotherapy (2018) Vol. Volume 7, pp. 65-77
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

A review of glioblastoma immunotherapy
Ravi Medikonda, Gavin P. Dunn, Maryam Rahman, et al.
Journal of Neuro-Oncology (2020) Vol. 151, Iss. 1, pp. 41-53
Closed Access | Times Cited: 230
Oncolytic Viruses and the Immune System: The Dynamic Duo
Ana Lemos de Matos, Lina S. Franco, Grant McFadden
Molecular Therapy — Methods & Clinical Development (2020) Vol. 17, pp. 349-358
Open Access | Times Cited: 205
Virus-Based Immunotherapy of Glioblastoma
Miika Martikainen, Magnus Essand
Cancers (2019) Vol. 11, Iss. 2, pp. 186-186
Open Access | Times Cited: 128
The role of neoantigen in immune checkpoint blockade therapy
Ming Yi, Shuang Qin, Weiheng Zhao, et al.
Experimental Hematology and Oncology (2018) Vol. 7, Iss. 1
Open Access | Times Cited: 119
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
Luke Russell, Kah Whye Peng, Stephen J. Russell, et al.
BioDrugs (2019) Vol. 33, Iss. 5, pp. 485-501
Open Access | Times Cited: 112
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
Laura Evgin, Amanda L. Huff, Phonphimon Wongthida, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 91
Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy
Hong-My Nguyen, Kirsten Guz-Montgomery, Dipongkor Saha
Cells (2020) Vol. 9, Iss. 2, pp. 400-400
Open Access | Times Cited: 75
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Sharmila Nair, Luciano Mazzoccoli, Arijita Jash, et al.
JCI Insight (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 69
Advances in engineering local drug delivery systems for cancer immunotherapy
Peter Abdou, Zejun Wang, Qian Chen, et al.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2020) Vol. 12, Iss. 5
Open Access | Times Cited: 57
Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
Luyao Wang, Qingxia Ma, Ruixue Yao, et al.
International Immunopharmacology (2019) Vol. 79, pp. 106088-106088
Closed Access | Times Cited: 56
Development of oncolytic virotherapy: from genetic modification to combination therapy
Qiaoshuai Lan, Shuai Xia, Qian Wang, et al.
Frontiers of Medicine (2020) Vol. 14, Iss. 2, pp. 160-184
Open Access | Times Cited: 56
Therapeutic Vaccination for HPV-Mediated Cancers
Flora Yan, Lindsay G. Cowell, Anna Tomkies, et al.
Current Otorhinolaryngology Reports (2023) Vol. 11, Iss. 1, pp. 44-61
Open Access | Times Cited: 22
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
M. Chiu, E Armstrong, Vicki Jennings, et al.
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 6, pp. 635-652
Closed Access | Times Cited: 48
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Justyna Mączyńska, Florian Raes, Chiara Da Pieve, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 25
Perspectives on immunotherapy via oncolytic viruses
Alberto Reale, Adriana Vitiello, Valeria Conciatori, et al.
Infectious Agents and Cancer (2019) Vol. 14, Iss. 1
Open Access | Times Cited: 36
Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
Miaoqin Chen, Shiman Hu, Yiling Li, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 34
Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
Bangxing Hong, Upasana Sahu, Matthew P. Mullarkey, et al.
Viruses (2022) Vol. 14, Iss. 1, pp. 118-118
Open Access | Times Cited: 22
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
Luyao Wang, Zongxing Yang, Fucheng Guo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab
Akihiro Yamada, Mary Choules, Frances A. Brightman, et al.
CPT Pharmacometrics & Systems Pharmacology (2025)
Open Access
Immunotherapeutic Challenges for Pediatric Cancers
Brian Hutzen, Mohammed G. Ghonime, Joel Lee, et al.
Molecular Therapy — Oncolytics (2019) Vol. 15, pp. 38-48
Open Access | Times Cited: 33
Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges
Huitao Liu, Honglin Luo
Viruses (2021) Vol. 13, Iss. 6, pp. 1082-1082
Open Access | Times Cited: 26
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
Víctor Cervera-Carrascón, Dafne C.A. Quixabeira, João M. Santos, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 26
Novel Delivery Systems for Checkpoint Inhibitors
Purushottam Lamichhane, Rahul R. Deshmukh, Julie K. Brown, et al.
Medicines (2019) Vol. 6, Iss. 3, pp. 74-74
Open Access | Times Cited: 25
Immunotherapy and other systemic therapies for cutaneous SCC
Alexander Guminski, B. Stein
Oral Oncology (2019) Vol. 99, pp. 104459-104459
Closed Access | Times Cited: 23
The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
Xin Xie, Jingwen Lv, Wei Zhu, et al.
Translational Oncology (2021) Vol. 15, Iss. 1, pp. 101287-101287
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top